An observational study in Advanced or Metastatic Renal Cell Carcinoma and Renal Cancer, sponsored by Pfizer. Completed at 14 sites in Slovakia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-09.
Sponsored by Pfizer · Observational
Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.
Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's enrollment of 121 is below the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy.
Exclusion Criteria:
125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
Drug: Sutent
50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
Also known as: sunitinib malate
Increased knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib
Time frame: 36 months
Dose modifications
Time frame: 36 months
Incidence of new diagnosed hypertension
Time frame: 36 months
Incidence of new diagnosed hypothyroidism
Time frame: 36 months
Safety of sunitinib malate in "real-life" setting
Time frame: 36 months
Efficacy of sunitinib malate in "real-life" setting
Time frame: 36 months
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer